Analysis

The argument that free trade is always the correct policy is based on a flawed welfare analysis. Free trade results in winners and losers and economists are not competent to analyze the impact on well-being as a whole or the spillover social consequences of the discontent of the losers.

From political slugfests to classroom battles, historian Marc Egnal talks with INET’s Lynn Parramore about the need for a new approach to our national story.
In his new book Challenging the Myths of U.S. History, historian Marc Egnal takes aim at the stories Americans like to tell themselves -- on both the right and the left.

The idea is finally catching on, but many still miss how deeply it’s driving inflation, masking wage losses, and complicating recovery.
Lately, you’ve probably seen headlines highlighting what some call a surprising truth: the richest Americans -- who’ve enjoyed years of income and wealth growth -- are the ones keeping the economy afloat with their spending. Meanwhile, most people struggle to keep up with rising costs.

Here’s the breakdown on what’s really driving America’s runaway drug prices -- and whether any of the current plans stand a chance to lower your pharmacy bill.
When it comes to the sickening cost of prescription drugs in America, this much is true: Big Pharma didn’t get rich by playing nice. It got rich playing Wall Street games.

For decades, economist William Lazonick has been exposing how Pharma’s Wall Street-driven business model doesn’t just lead to sky-high drug prices, but actually stifles innovation, too.